How to personalise treatment regimes in MS and related disorders? This topic will take centre stage at ECTRIMS 2025.
|
In Scientific Session 10, Professor Prof Fredrik Piehl and Prof Ho Jin Kim will discuss the efficacy, effectiveness, and safety of HET different intervals and doses in MS, NMOSD, and MOGAD. Prof Daniel Ontaneda and Prof Sandra Vukusic will chair the session.
Biomarkers offer promising potential to support diagnosis, prognosis, and therapeutic decision-making in multiple sclerosis. However, despite notable advances, several challenges remain including standardization, clinical validation, and integration into routine practice [1]. Advancing personalised treatment in MS remains challenging due to the limited availability of evidence-based biomarkers [2] . Although novel candidates like neurofilament light chain are promising, their widespread use is hindered by the need for consistent assay methods and robust clinical validation[2].
Professor Daniel Ontaneda from Cleveland Clinic in Ohio says:
“The first invited scientific talk will discuss how we can modify the regime, the dosing interval, and the frequency of treatments specifically for each individual patient in MS. The second will cover the same topic in NMOSD and related demyelinating diseases.”
The two scientific talks will cover very pragmatic ways of personalising treatment in individuals with MS, NMOSD, and MOGAD. Interviewed for our Spotlight, Professor Piehl said, “We need to personalise treatment and evaluate the pros and cons for each person with MS.”
Over the past two decades, MS treatment has evolved with an increasing availability of effective disease-modifying therapies [3].Therapy selection in MS is increasingly complex and should be guided by a solid understanding of drug mechanisms and risk–benefit profiles [3]. Before starting a treatment, neurologists should make several careful consideration – particularly, the disease status, its prognostic factors and comorbidities, future pregnancy, prior treatment response, and patient risk tolerance to optimize outcomes [3]. Risk mitigation strategies should be tailored to individuals with MS, particularly those at higher risk, such as children, pregnant women, people with comorbidities, and people living in areas with endemic infections [4].
Don’t miss this and many other thought-provoking sessions at ECTRIMS 2025. Join us in Barcelona, 24–26 September 2025, to explore the latest in MS research, clinical care, and innovation. Register now and view the full programme to start planning your congress experience.
References:
[1] Di Filippo M. et al. Lancet Reg. Health–Eur. 2024; 44.
[2] Rotstein D and Montalban X. Nat. Rev. Neurol. 2019; 15(5): 287-300.
[3] Comi G, Radaelli M and Sørensen PS Lancet 2017; 389.10076: 1347-1356.
[4] Tur C et al. Mult. Scler. J. 2022; 28(9): 1424-1456.